Premaitha opens new lab dedicated to IONA test

Premaitha opens new lab dedicated to IONA test

Biotech specialist Premaitha Health has opened a dedicated laboratory at its Manchester Science Park base which triples its capacity to respond to demand for the IONA test from clinicians.

IONA is Premaitha’s newly-launched non-invasive prenatal test (NIPT) for Down’s Syndrome, and other serious genetic conditions such as Patau’s Syndrome and Edwards’ Syndrome by analysing cell-free DNA from a sample of maternal blood. Premaitha said the new Care Quality Commission (CQC)-accredited, clinical laboratory will enable it to dramatically increase throughput, of the maternal blood samples analysed each month using the IONA test.

Premaitha chief finanicial officer Barry Hextall said: “The decision to expand our NIPT in-house service has been driven by demand from clinicians for the fast, accurate and accredited results provided by the IONA test. These additional laboratory facilities and our extended team of specialists who run the IONA test service means we can offer the benefits of the first and only CE-marked (European approved) in-vitro diagnostic product for NIPT to more pregnant women, sooner. This also fulfils one of the commercialisation objectives stated at the time of the recent fundraising.”

See article in full at

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.